 - Completion of previous anti-cancer therapy e.g. chemotherapy, immunotherapy, tyrosine kinase inhibitor, or radiation therapy at least 2 weeks before study drug initiation, with resolution of all associated toxicity to Grade 1 or Baseline prior to PLX8394 administration. 